Publicada em 2 de nov de Enviar pesquisa. O slideshow foi denunciado. Mycobacterium Tuberculosis.
|Country:||Antigua & Barbuda|
|Published (Last):||17 September 2014|
|PDF File Size:||5.3 Mb|
|ePub File Size:||19.47 Mb|
|Price:||Free* [*Free Regsitration Required]|
Rational approach in the new antituberculosis agent design: inhibitors of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Unitermos: Tuberculose. In conjunction with the spread of HIV infection, tuberculosis TB has been among the worldwide health threats. Mycobacteria resistance to the drugs currently used in the therapeutics is the main cause of TB resurgence. In view of this severe situation, the new and selective anti-TB design is of utmost importance.
Fatty acid biosynthesis is a prokariontes and eucariontes biochemical process that supplies essential precursors for the assembly of important cellular components, such as phospholipids, lipoproteins, lipopolysaccharides, mycolic acids and cellular envelope. However, the biochemical and functional differences between the bacterial and mammals' fatty acid synthetic pathway have endowed the mycobacterial enzymes with distinct properties. These provide valuable opportunities for structure- or catalytic mechanism-based design of selective inhibitors as novel anti-TB drugs with improved properties.
The enoyl-reductases are essential enzymes in the fatty acids elongation pathway towards the mycolic acids, the main mycobacteria cell wall constituents, biosynthesis and so they are potential targets to the rational new antimycobacteria drug design.
This paper highlights recent approaches regarding the design of new anti-TB agents, particularly, the enoyl-ACP reductase inhibitors.
Uniterms: Tuberculosis. Mycolic acids. Mycobacteria drug resistance. Rozwaski et al. Em geral, as tiofeno-diazoborinas foram os inibidores mais potentes, seguidos pelas benzo-diazoborinas e furano-diazoborinas, enquanto que as pirrol-diazoborinas foram totalmente inativas.
Estes pesquisadores isolaram cepas de E. Foram utilizados Mechanism of action of diazaborines. A mechanism of drug action revealed by structural studies of enoyl reductase.
Science , v. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology , v.
Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Trends Microbiol. Mycolic acids: structure, biosynthesis and physiological functions.
Chemotherapy of experimental tuberculosis - V. Isonicotinic acid hydrazide nydrazid and related compounds. Chemotherapy of experimental tuberculosis - VI. Derivatives of isoniazid. Chemotherapy of experimental tuberculosis - VII.
Heterocyclic acid hydrazides and derivatives. Triclosan: applications and safety. The envelope of mycobacteria. Guidebook on molecular modeling in drug design. San Diego: Academic Press, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Crystal structure and fuction of the isoniazid target of Mycobacterium tuberculosis.
Dias, M. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP CoA reductase from Mycobacterium tuberculosis. Global tuberculosis incidence and mortality during WHO, v. Tuberculosis , v. Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues. HE, X. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis.
Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. A triclosan-resistant bacterial enzyme. Nature , v. Lipid biosynthesis as a target for antibacterial agents. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Broad spectrum antimicrobial biocides target the FabI component of fatty acid biosynthesis.
HEYM, B. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet , v. Antituberculosis drugs: ten years of research. Mycobacterial cell wall: structure and role in natural resistance to antibiotics.
FEMS Microbiol. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. KRUH, N. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis. Protein Sci. KUO, M. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data.
Overexpression of inhA, but not kasA , confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis , M. LEVY, C. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-acp reductase. Critical review of the role of HTS in drug discovery.
Today , v. Mechanistic diversity and regulation of Type II fatty acid synthesis. Triclosan targets lipid synthesis. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Agents Chemother. Characterization of the catalase-peroxidase gene katG and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.
Recent advances in new structural classes of anti-tuberculosis agents. Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents. Drug Targets , v. PAN, D. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis.
Quantitative structure -based design: Formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis , by triclosan and isoniazid. Biochemistry , v. An approach for the rational design of new antituberculosis agents. Rational design of new antituberculosis agents: Receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
An introduction to medicinal chemistry. Oxford: Oxford University Press, Discovery of a novel and potent class of FabI-directed antibacterial agents. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. Tuberculosis, focus on tropical diseases. Anaesthesia Crit. Care , v. Structural basis and mechanism of enoyl reductase inhibition by triclosan. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
ACS Chem. Constructing protein models for ligand-receptor binding thermodynamic simulations: An application to a set of peptidometic rennin inhibitors. The mechanism of isoniazid killing: Clarity through the scope of genetics.
Rational approach in the new antituberculosis agent design: inhibitors of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Unitermos: Tuberculose. In conjunction with the spread of HIV infection, tuberculosis TB has been among the worldwide health threats. Mycobacteria resistance to the drugs currently used in the therapeutics is the main cause of TB resurgence. In view of this severe situation, the new and selective anti-TB design is of utmost importance. Fatty acid biosynthesis is a prokariontes and eucariontes biochemical process that supplies essential precursors for the assembly of important cellular components, such as phospholipids, lipoproteins, lipopolysaccharides, mycolic acids and cellular envelope. However, the biochemical and functional differences between the bacterial and mammals' fatty acid synthetic pathway have endowed the mycobacterial enzymes with distinct properties.
Identificación de especies micobacterianas en Cuba
Estudiante de doctorado en Medicina Tropical. Universidad de Cartagena. Docente Investigadora Universidad de Cartagena. Directora regional Doctorado Medicina Tropical.
- CY7C68013A MINI BOARD PDF
- ESS ESS BATH FITTINGS CATALOGUE PDF
- HET INSTALLATIEBOEK PDF
- EMPIRES OF THE WORLD NICHOLAS OSTLER PDF
- LORELEI JAMES COWBOY CASANOVA FREE PDF
- LOTAKAMBAL BY SANJIB CHATTOPADHYAY PDF
- BARRERA HEMATOTESTICULAR PDF
- 610 TOEIC PHOTOGRAPHS PDF
- KRAJEWSKI ADMINISTRACION DE OPERACIONES PDF